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Elisabeth R. Mathiesen1,4*, Henning Andersen2, Sofia I. I. Kring3 and Peter Damm1,4Abstract
Background: There are a lack of data regarding the effect of basal insulin analogues on rates of events like
congenital malformation and perinatal mortality in diabetic pregnancy.
Methods: The present study is a prospective, non-interventional, multicentre cohort study conducted in seven
countries, designed to assess the safety of insulin detemir during pregnancy, and to monitor the health status of
resulting infants (exposed in utero) up to 1 year of age. The study population includes women with type 1 or type
2 diabetes, who are pregnant and being treated with insulin. Data will be collected in the context of routine
practice. The primary endpoint is the proportion of pregnancies in women treated with insulin detemir, compared
with other basal insulin regimens, which do not result in any of the following events: major congenital
malformations, perinatal death or neonatal death. A sample size of 3075 pregnancies was calculated to provide an
80% power to detect a difference of 3.5% between groups in the primary endpoint at a 5% level.
Discussion: The study will also examine other important maternal endpoints (e.g., incidences of severe
hypoglycaemia and pre-eclampsia) and perinatal outcomes such as overweight neonates, as well as infant
outcomes at 1 year of age. It has a fixed recruitment period from 2013 to 2018, enrolling all eligible patients, and is
expected to inform future prescribing with basal insulins in diabetic pregnancy.
Trial registration: ClinicalTrials.gov: NCT01892319 (date registered: 27.06.2013).
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Pregnancy in women with diabetes is associated with an in-
creased risk of complications for the mother and the fetus/
newborn. The most severe of these include congenital mal-
formations, as well as perinatal and neonatal mortality.
Three recent nationwide population-based studies
conducted in Scandinavia have shed light on the risk of
such events in pregnancies among women with type 1
diabetes (T1D) [1–3]. Odds ratios (ORs) of stillbirth
(ORs: 3.3 in one study and 3.6 in another), perinatal
mortality (ORs: 3.3 in one study and 2.9 in another) and
infant death in the first year of life (OR: 1.9) were all
shown to be significantly higher among T1D than non-
T1D pregnancies [1, 3]. Odds ratios of congenital abnor-
malities were also significantly elevated (ORs: 2.5 in one
study and 2.1 in another) [1, 2].
Furthermore, in a prospective Danish multicentre
study of >1000 T1D pregnancies, the perinatal annual
mortality rate was 3.1% in women with T1D compared
with 0.75% in the background population (OR: 4.1), and
the annual rate of congenital malformation was 5.0%,
compared with 2.8% in the background population (OR:
1.7) [4]. In this study, serious adverse outcomes (peri-
natal death and/or congenital malformations) were asso-
ciated with higher glycated haemoglobin (HbA1c) levels
before and during pregnancy [4]. Furthermore, even
small elevations in HbA1c in pregnant women with dia-
betes have been associated with significantly increased
rates of congenital malformations [5]. Hence, normogly-
caemia should be the target in pregnant women with
diabetes and in those planning pregnancy. To achieve
this, insulin will be required in all T1D patients, and in
many type 2 diabetes (T2D) patients. A literature review
revealed that available data on the use of basal insulins
(including long-acting insulin analogues and neutral pro-
tamine Hagedorn [NPH] insulin) in pregnant women
with diabetes come largely from retrospective studies
[6]. These data suggest that basal insulins can be effect-
ive and safe in women with T1D during pregnancy. In a
recent retrospective analysis of 113 T1D pregnancies in
which women used insulin detemir (IDet) or insulin
glargine (IGlar), glycaemic control and pregnancy out-
comes were comparable between the two groups with
regard to congenital malformations, as well as perinatal
and neonatal mortality. There were no perinatal deaths
and two offspring (2%, one in each group) were born
with a major congenital malformation [7].
However, there are relatively few prospective data on
insulin use in pregnancy. Only one randomised con-
trolled trial (RCT) has been performed investigating the
use of a basal insulin analogue: a trial comparing IDet
with NPH insulin, both in combination with insulin
aspart, in pregnant women with T1D [8]. In this study,
IDet resulted in significantly lower fasting plasmaglucose (FPG) in pregnancy compared with NPH insulin,
with similar HbA1c levels and rates of hypoglycaemia
[8]. This trial also suggested that both insulins were well
tolerated with regard to perinatal outcomes [9].
While these data are valuable, RCTs are not the best
method for evaluating the occurrence of rare events like
congenital malformations and perinatal/neonatal mortal-
ity. Population reports have reported outcome incidences,
but not in relation to specific treatments [10–13]. Instead,
large observational studies are required to assess safety
and to attempt to detect this type of event, hence, such a
study is warranted.
In addition to this clinical need, the European Medicines
Agency (EMA) has requested that a post-authorisation
safety study (PASS) be performed to monitor the long-
term safety of IDet in pregnant women, covering both
gestation and lactation.
The present study was therefore initiated to evaluate
the safety of IDet in pregnant women, with a focus on
the occurrence of malformations and perinatal/neonatal
death. It will also examine other important maternal
endpoints (e.g., incidences of hypoglycaemia and pre-
eclampsia) and perinatal outcomes (e.g., incidences of
overweight neonates/large for gestational age [LGA]), as
well as infant outcomes at 1 year of age.
Methods/design
This study is an international, prospective, non-
interventional, multicentre cohort study to monitor and
assess the safety of IDet in comparison with other types
of insulin treatment during pregnancy, and to monitor
the health status of the resulting infants (who were ex-
posed in utero) at 1 month and 1 year of age. The large-
scale data collection undertaken in this study will allow
comparison and analysis of the occurrence of events be-
tween the various insulin treatment regimens. The same
parameters will also be monitored for other injectable
antidiabetic treatment regimens used during pregnancy.
The study is non-interventional. The assignment of
patients to a particular therapeutic strategy is not de-
cided in advance by a trial protocol but instead falls
within current practice. Data will be collected in the
context of routine practice, with very few exclusion cri-
teria, and hence the results are expected to be more
broadly applicable to the real-world population than
those of typical RCTs.
The primary objective is to estimate the proportion of
pregnancies in women treated with IDet, compared with
other basal insulin regimens, which do not result in any
of the following events: major congenital malformations,
perinatal death or neonatal death (assessed at up to
4 weeks after delivery). The definitions of these and
other key terms, within the context of this trial, are pro-
vided in Table 1.
Table 1 Definitions of key terms
Term Definition
Congenital
malformation
A morphological defect of an organ, part of an organ or larger region of the body resulting from an intrinsically abnormal
developmental process
Foetal macrosomia Birth weight above 4 kg
Large for gestational
age
Live born infant with birth weight >90th percentile for gestational age and sex according to local reference
Major malformation A life-threatening structural anomaly or an abnormality likely to cause significant impairment of health or functional capacity
and which needs medical or surgical treatment; examples are abnormalities likely to lead to serious handicap or likely to lead
to major cosmetic defects (e.g., cleft lip) and which may require major surgery to repair (e.g., atrial septal defect or ventricular
septal defect)
Major
hypoglycaemia
A hypoglycaemic episode in which the patient is not able to treat themselves and in which oral carbohydrates, glucagon or
intravenous glucose has to be administered to the patient by another person because of severe central nervous system
dysfunction
Neonatal death Death of an infant between 7 and 28 completed days after delivery
Perinatal death Death of a foetus/infant at ≥22 completed gestational weeks and <1 completed week after delivery
Preterm delivery Delivery before 37 completed gestational weeks
Pre-eclampsia A condition in pregnancy characterised by new onset of abrupt hypertension (≥140/90 mmHg documented on two
occasions, ≥6 h and ≤7 days apart) and proteinuria/albuminuria
Spontaneous
abortion
A naturally occurring termination of a pregnancy before 22 completed gestation weeks
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(September 2013 to September 2018), and will in-
clude gestation and follow-up of infants at 1 month
and 1 year of age. The planned enrolment is 3055
patients.
The study population will include women with T1D
or T2D (as assessed from maternal medical history)
who are pregnant and being treated with insulin or
other injectable antidiabetic treatment regimens, and
who have not changed their basal insulin or other in-
jectable antidiabetic treatment for 4 weeks prior to
and following conception. Inclusion and exclusion cri-
teria are listed in Table 2.
Study endpoints
The primary endpoint is the proportion of pregnancies
in women treated with IDet, compared with other basal
insulin regimens, which do not result in any of the fol-
lowing events: major congenital malformations, perinatalTable 2 Inclusion and exclusion criteria
Inclusion criteria
• Woman with a positive pregnancy test
• Type 1 diabetes or type 2 diabetes, diagnosed prior to conception
• Treated with unchanged basal insulin or other injectable antidiabetic
treatment (for those not treated with basal insulin) for 4 weeks prior to
and following conception
• Informed consent obtained before any data collection
Exclusion criteria
• Women who have been pregnant for >12 weeks at baseline visit
confirmed by ultrasounddeath or neonatal death (assessed at up to 4 weeks after
delivery).
Key secondary endpoints relate to outcomes with
IDet versus other basal insulin regimens for the
mother, the fetus and the infant at 1 year of age. Ma-
ternal endpoints include the incidence of major
hypoglycaemia during pregnancy, the proportion of
pregnancies complicated by pre-eclampsia and meta-
bolic control (measured as HbA1c). Perinatal outcome
endpoints include the proportion resulting in fetal
macrosomia, LGA, preterm delivery or spontaneous
abortion. Infant endpoints assessed at 1 year of age
include height, weight, the proportion with diabetes,
and the proportion with changes (progression/regres-
sion) of major congenital malformations.
Safety data will also be collected in the pregnant
women participating in the study, as well as in their off-
spring up to 1 year of age.
For analyses of the primary and secondary endpoints,
only women treated with basal insulin will be included.
However, information on all insulins and other injectable
antidiabetic treatment regimens will be collected to fa-
cilitate comparison and analysis of outcomes in IDet-
treated patients versus, for example, patients treated
with an insulin pump.
Any change in basal insulin after the baseline visit will
lead to exclusion from the statistical analyses of the pri-
mary and secondary endpoints, but not from the study.
However, changes in dosage or dose interval, or add-on/
removal of bolus insulin, oral antidiabetic drugs and/or
glucagon-like peptide-1 (GLP-1) agonists, will not lead
to exclusion from the analyses.
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The frequency of visits will be determined by the indi-
vidual study sites, and the data will be gathered as part
of standard local routine. Only data collection at 1 month
and at 1 year follow-up will be performed separately for
the purpose of the study.
Data will be collected at various time points, including
baseline (occurring as soon as the woman has discovered
her pregnancy through a positive pregnancy test), stand-
ard routine visits throughout pregnancy, delivery (relat-
ing both to the mother and the neonate), 1-month
follow-up and end of study (1-year follow-up) (Fig. 1).
Postpartum follow-up at 1 month and 1 year will be per-
formed using questionnaires (see Additional files 1 and 2)
and telephone interviews. The 1-month follow-up will
collect information on height, weight, neonatal death
(yes or no), congenital malformations not detected at de-
livery, duration of exclusive/partial lactation and any ad-
verse events (AEs) relating to the neonate. The 1-year
follow-up will collect information on the duration of ex-
clusive and any lactation, height, weight, diabetes in the
infant (yes or no), changes in major congenital malforma-
tions and any AEs relating to the infant.
Statistical considerations
The analysis set will consist of all pregnancies among
patients who are treated with basal insulin and have not
changed basal insulin product for 4 weeks prior to con-
ception and during pregnancy. Continuous variables will
be summarised with descriptive statistics, and categorical
variables will be displayed in frequency tables.
The primary endpoint will be analysed using a logistic
regression model that will include treatment group, study
site, race, hypertension, major hypoglycaemic events dur-
ing pregnancy, folic acid intake and use of GLP-1 agonists
during pregnancy as factors. HbA1c at the start of preg-
nancy, the end of the first trimester and the end of the
second trimester, age and body mass index at baseline,Fig. 1 Study roadmap for each subjectduration of diabetes, blood pressure and previous peri-
natal complications will be included as covariates. The
primary endpoint will be computed for the IDet group
and for the ‘other basal insulin’ group and the absolute
difference between these proportions calculated, along
with the 95% CI and the p-value using Fisher’s exact test.
For infant endpoints at 1 year, the proportions will also
be analysed using logistic regression. Factors and covari-
ates will be as per the primary endpoint. Analyses regard-
ing height and weight will also be adjusted for exclusive
and/or partial lactation period. Similar analyses will be
performed for all other endpoints that are proportions.
Means of the continuous endpoints will be compared
between the two groups using an analysis of covariance
model.
The incidence of major hypoglycaemia during preg-
nancy will be computed for both treatment groups.
Observations of possible clinical importance (such as
the primary endpoint split out according to diabetes type,
insulin analogue or use of an insulin pump) will be pre-
sented using descriptive statistics.
All statistical analyses will be performed using appro-
priate statistical software, and tests will be performed as
two-sided tests with a significance level of 0.05.
Determination of sample size
The sample size calculation was derived from the pri-
mary endpoint, based on patients with none of the three
individual outcomes: major congenital malformations,
perinatal death or neonatal death. The probability of this
combination of endpoints is not known within the litera-
ture. However, based on data from a UK population study
[10], which are in line with results from other European
countries [1, 2, 4, 11–13], the proportion of pregnancies
with any of the above outcomes is estimated at 8.2%:
major congenital malformations, 4.5%; perinatal death,
3%; neonatal death, 0.9% (8.2% is computed under the as-
sumption that the individual outcomes are independent).
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outcomes is therefore estimated at 91.8%.
The goal is to be able to detect a difference of 3.5% be-
tween the proportions without the combined endpoint
in the IDet group compared with the other basal insulin
regimens group. Assuming a maximum 1:2 split between
the two groups (IDet group: other basal insulin regimens
group), a sample size of 1833 pregnancies is needed to
have 80% power of achieving significance at a 5% level.
To achieve a total of 1833 pregnancies for the assess-
ment of the primary endpoint, the planned number of pa-
tients to be included during the 5 years of the recruitment
period is 3075. This number is based on the expectation
that ~20% of pregnancies will result in a spontaneous
abortion, ~10% will be treated with other antidiabetic
injectables or will change basal insulin treatment and
~10% will be lost to follow-up, leaving 60% of pregnancies
(i.e., 1833) assessable for the primary endpoint.
Study organisation
The study is being conducted across approximately 53
study sites in 14 countries. The anticipated numbers of
patients per country are as follows: Croatia, 355;
Denmark, 620; Finland, 100; France, 150; Germany, 135;
Israel, 350; Italy, 130; Netherlands, 100; Poland, 200;
Romania, 60; Spain, 375; and UK, 300. Additional coun-
tries and study sites might be included during the study
period. Sites have relatively similar standard routine
procedures with regard to the treatment of women with
diabetes during pregnancy and have a relatively high
prescription rate of IDet. The projected study timeline is
given in Fig. 2.
The study is sponsored by a research grant from Novo
Nordisk A/S. A Novo Nordisk A/S internal safety com-
mittee will perform ongoing safety surveillance. The
study will be conducted in accordance with Good
Pharmacoepidemiology Practice and the Declaration of
Helsinki, and has been approved separately in each of
the participating countries (national health authorities/
local institutional review boards/independent ethics
committee). Written informed consent is required fromFig. 2 Study timeline. FPFV, first patient first visit; LPFV, last patient first visiall study participants. The trial registration number is
NCT01892319 (www.clinicaltrials.gov).
Discussion
Outside of pregnancy, long-acting insulin analogues im-
prove glycaemic control, and are associated with lower
rates of hypoglycaemia than human insulins [14, 15].
Among the insulin analogues, the European Union labels
for both IDet and IGlar allow for consideration of use in
pregnancy [16, 17]. In the case of IGlar, this is based on
postmarketing data; for IDet, an RCT has been per-
formed, demonstrating significantly lower FPG and non-
inferior HbA1c in late pregnancy and similar rates of
hypoglycaemia compared with NPH insulin [7].
However, none of these studies were sufficiently large to
accurately evaluate the incidence of events such as con-
genital malformations and perinatal/neonatal mortality in
patients receiving insulin during pregnancy. Hence, this
long-term, prospective, epidemiological study was
initiated-the first of its kind in pregnant women with
diabetes.
Although the primary endpoint is based around the in-
cidence of malformation and mortality, the study will
also examine a number of other important endpoints.
For example, data on incidences of pre-eclampsia, fetal
macrosomia and LGA will be collected. Each of these
has been shown to occur more frequently in T1D than
control pregnancies. Indeed, in a Swedish population
study, odds ratios were 4.5 for pre-eclampsia and 11.4
for LGA [1].
Data on the incidence of maternal hypoglycaemia will
also be examined in the present study, and compared be-
tween different insulin treatments. Severe hypoglycaemic
episodes are common in diabetic pregnancy, particularly
in the first trimester, and are associated with a variety of
factors, including impaired hypoglycaemia awareness, long
duration of diabetes, fluctuating plasma glucose values
and excessive use of supplementary insulin injections be-
tween meals [18].
Furthermore, the study will also examine the health of
the infant at 1 year of age, including the proportion witht; LPLV, last patient last visit
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tions, as well as early growth (height and weight) and
breastfeeding history. Data on such outcomes are cur-
rently lacking, and so this trial is expected to fill an im-
portant gap in understanding.
The very liberal inclusion and exclusion criteria of this
study mean that the population will be largely unse-
lected, as compared with the highly selected populations
typically eligible for RCTs. The results will therefore be
more broadly applicable to the real-world population of
pregnant women with diabetes. Furthermore, as the
study collects data based on standard routine care, par-
ticipation will be substantially less demanding on the
women recruited, as compared with RCTs.
In summary, this is an international, prospective, non-
interventional, multicentre, cohort study designed to as-
sess the safety of IDet in comparison with other types of
insulin treatment during pregnancy, and to monitor the
health status of the resulting infants - who were exposed
in utero - up to 1 year of age. The planned enrolment of
3075 patients is sufficiently large to allow comparison of
the frequency of rare events, such as congenital malfor-
mations and perinatal/neonatal death, between the vari-
ous insulin treatment regimens. The study will therefore
provide valuable information on these events, as well as
other relevant maternal, pregnancy and infant-related
endpoints, to inform future prescribing with basal insu-
lins in diabetic pregnancy.
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Additional file 2: 12-month questionnaire. (PDF 136 kb)
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